The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity profiles

R. Yarchoan, H. Mitsuya, J. M. Pluda, K. S. Marczyk, R. V. Thomas, N. R. Hartman, P. Brouwers, C. F. Perno, J. P. Allain, D. G. Johns, S. Broder

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

2',3'-Dideoxyinosine (didanosine; ddI) was administered to 37 adults with AIDS or AIDS-related complex in an escalating-dose phase I study. Groups of three or four patients received intravenous dosages of 0.4 mg/(kg·d) to 25.6 mg/(kg·d) divided into two or three daily doses for 2 weeks, followed by oral ddI at twice the intravenous dosages. When given with antacids, ddI was well absorbed by the oral route and penetrated into the cerebrospinal fluid. The patients had an increase in mean number of CD4+ cells from 114/mm3 at entry to 161/mm3 at week 6 (P = .00004). They also had an increase in the CD4+/CD8+ ratio and in total number of lymphocytes. Sixteen of 18 evaluable patients had a decrease in levels of human immunodeficiency virus p24 antigen by week 6 (P = .0034). Many patients reported increased energy and appetite and gained weight. Dose-limiting toxicities at high dosages were painful peripheral neuropathy and sporadic pancreatitis. However, dosages up to 9.6 mg/kg (kg·d) have been tolerated in patients for 11-14 months. Thus, ddI has activity against human immunodeficiency virus at dosages that can be tolerated for ~1 year. However, life-threatening pancreatitis is a possible complication even at low dosages, and the best ways to manage and avoid adverse effects are still under study.

Original languageEnglish
JournalReviews of Infectious Diseases
Volume12
Issue numberSUPPL. 5
Publication statusPublished - 1990

Fingerprint

Didanosine
AIDS-Related Complex
National Cancer Institute (U.S.)
Acquired Immunodeficiency Syndrome
Pancreatitis
HIV
Antacids
CD4-CD8 Ratio
Lymphocyte Count
Peripheral Nervous System Diseases
Appetite
Cerebrospinal Fluid
Cell Count
Antigens
Weights and Measures

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex : Analysis of activity and toxicity profiles. / Yarchoan, R.; Mitsuya, H.; Pluda, J. M.; Marczyk, K. S.; Thomas, R. V.; Hartman, N. R.; Brouwers, P.; Perno, C. F.; Allain, J. P.; Johns, D. G.; Broder, S.

In: Reviews of Infectious Diseases, Vol. 12, No. SUPPL. 5, 1990.

Research output: Contribution to journalArticle

Yarchoan, R, Mitsuya, H, Pluda, JM, Marczyk, KS, Thomas, RV, Hartman, NR, Brouwers, P, Perno, CF, Allain, JP, Johns, DG & Broder, S 1990, 'The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity profiles', Reviews of Infectious Diseases, vol. 12, no. SUPPL. 5.
Yarchoan, R. ; Mitsuya, H. ; Pluda, J. M. ; Marczyk, K. S. ; Thomas, R. V. ; Hartman, N. R. ; Brouwers, P. ; Perno, C. F. ; Allain, J. P. ; Johns, D. G. ; Broder, S. / The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex : Analysis of activity and toxicity profiles. In: Reviews of Infectious Diseases. 1990 ; Vol. 12, No. SUPPL. 5.
@article{dbb4da26edeb4bf18070f1c59dee1693,
title = "The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity profiles",
abstract = "2',3'-Dideoxyinosine (didanosine; ddI) was administered to 37 adults with AIDS or AIDS-related complex in an escalating-dose phase I study. Groups of three or four patients received intravenous dosages of 0.4 mg/(kg·d) to 25.6 mg/(kg·d) divided into two or three daily doses for 2 weeks, followed by oral ddI at twice the intravenous dosages. When given with antacids, ddI was well absorbed by the oral route and penetrated into the cerebrospinal fluid. The patients had an increase in mean number of CD4+ cells from 114/mm3 at entry to 161/mm3 at week 6 (P = .00004). They also had an increase in the CD4+/CD8+ ratio and in total number of lymphocytes. Sixteen of 18 evaluable patients had a decrease in levels of human immunodeficiency virus p24 antigen by week 6 (P = .0034). Many patients reported increased energy and appetite and gained weight. Dose-limiting toxicities at high dosages were painful peripheral neuropathy and sporadic pancreatitis. However, dosages up to 9.6 mg/kg (kg·d) have been tolerated in patients for 11-14 months. Thus, ddI has activity against human immunodeficiency virus at dosages that can be tolerated for ~1 year. However, life-threatening pancreatitis is a possible complication even at low dosages, and the best ways to manage and avoid adverse effects are still under study.",
author = "R. Yarchoan and H. Mitsuya and Pluda, {J. M.} and Marczyk, {K. S.} and Thomas, {R. V.} and Hartman, {N. R.} and P. Brouwers and Perno, {C. F.} and Allain, {J. P.} and Johns, {D. G.} and S. Broder",
year = "1990",
language = "English",
volume = "12",
journal = "Reviews of Infectious Diseases",
issn = "0162-0886",
publisher = "University of Chicago Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex

T2 - Analysis of activity and toxicity profiles

AU - Yarchoan, R.

AU - Mitsuya, H.

AU - Pluda, J. M.

AU - Marczyk, K. S.

AU - Thomas, R. V.

AU - Hartman, N. R.

AU - Brouwers, P.

AU - Perno, C. F.

AU - Allain, J. P.

AU - Johns, D. G.

AU - Broder, S.

PY - 1990

Y1 - 1990

N2 - 2',3'-Dideoxyinosine (didanosine; ddI) was administered to 37 adults with AIDS or AIDS-related complex in an escalating-dose phase I study. Groups of three or four patients received intravenous dosages of 0.4 mg/(kg·d) to 25.6 mg/(kg·d) divided into two or three daily doses for 2 weeks, followed by oral ddI at twice the intravenous dosages. When given with antacids, ddI was well absorbed by the oral route and penetrated into the cerebrospinal fluid. The patients had an increase in mean number of CD4+ cells from 114/mm3 at entry to 161/mm3 at week 6 (P = .00004). They also had an increase in the CD4+/CD8+ ratio and in total number of lymphocytes. Sixteen of 18 evaluable patients had a decrease in levels of human immunodeficiency virus p24 antigen by week 6 (P = .0034). Many patients reported increased energy and appetite and gained weight. Dose-limiting toxicities at high dosages were painful peripheral neuropathy and sporadic pancreatitis. However, dosages up to 9.6 mg/kg (kg·d) have been tolerated in patients for 11-14 months. Thus, ddI has activity against human immunodeficiency virus at dosages that can be tolerated for ~1 year. However, life-threatening pancreatitis is a possible complication even at low dosages, and the best ways to manage and avoid adverse effects are still under study.

AB - 2',3'-Dideoxyinosine (didanosine; ddI) was administered to 37 adults with AIDS or AIDS-related complex in an escalating-dose phase I study. Groups of three or four patients received intravenous dosages of 0.4 mg/(kg·d) to 25.6 mg/(kg·d) divided into two or three daily doses for 2 weeks, followed by oral ddI at twice the intravenous dosages. When given with antacids, ddI was well absorbed by the oral route and penetrated into the cerebrospinal fluid. The patients had an increase in mean number of CD4+ cells from 114/mm3 at entry to 161/mm3 at week 6 (P = .00004). They also had an increase in the CD4+/CD8+ ratio and in total number of lymphocytes. Sixteen of 18 evaluable patients had a decrease in levels of human immunodeficiency virus p24 antigen by week 6 (P = .0034). Many patients reported increased energy and appetite and gained weight. Dose-limiting toxicities at high dosages were painful peripheral neuropathy and sporadic pancreatitis. However, dosages up to 9.6 mg/kg (kg·d) have been tolerated in patients for 11-14 months. Thus, ddI has activity against human immunodeficiency virus at dosages that can be tolerated for ~1 year. However, life-threatening pancreatitis is a possible complication even at low dosages, and the best ways to manage and avoid adverse effects are still under study.

UR - http://www.scopus.com/inward/record.url?scp=17644446926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644446926&partnerID=8YFLogxK

M3 - Article

C2 - 1974724

AN - SCOPUS:17644446926

VL - 12

JO - Reviews of Infectious Diseases

JF - Reviews of Infectious Diseases

SN - 0162-0886

IS - SUPPL. 5

ER -